Mantle Cell Lymphoma (MCL)
Mantle cell lymphoma (MCL) is characterized by the abnormal growth of B-cells in the lymph nodes, spleen, bone marrow, and other lymphoid tissues. Our company stands at the forefront, boldly pushing the boundaries of innovation, offering cutting-edge MCL drug and therapy development services. With an unwavering commitment to comprehensive diagnostics and targeted therapy approaches, we are revolutionizing the landscape of MCL drug and therapy development.
Introduction to Mantle Cell Lymphoma (MCL)
Mantle cell lymphoma (MCL) is a rare disease with an annual incidence of 1/200,000. MCL can be further classified into two major subgroups: nodal MCL and leukemic non-nodal MCL. MCL accounts for approximately 3-10% of all non-Hodgkin lymphomas and primarily affects older individuals, with a median age at diagnosis of around 60 years. MCL is known for its aggressive nature and often presents at an advanced stage.
Pathogenesis of Mantle Cell Lymphoma (MCL)
One of the key genetic abnormalities in MCL is the t(11;14)(q13;q32) translocation, which leads to the overexpression of the cyclin D1 protein. This translocation brings the cyclin D1 gene (CCND1) under the control of the immunoglobulin heavy chain gene (IGH), resulting in uncontrolled cell proliferation.
In addition to the t(11;14) translocation, several other genetic alterations have been identified in MCL. These include mutations in TP53, ATM, and NOTCH1 genes, as well as copy number alterations involving CDKN2A/B, RB1, and MYC. These aberrations disrupt important cellular processes, such as cell cycle control, DNA damage response, and signaling pathways involved in cell survival and proliferation.
Fig.1 The development of mature small B-cell lymphomas. (Wagner V. P., et al., 2021)Diagnostics Development of Mantle Cell Lymphoma (MCL)
- Cyclin D1 as a Diagnostic Marker
The overexpression of cyclin D1, resulting from the t(11;14) translocation, is a hallmark feature of MCL. Immunohistochemical staining for cyclin D1 protein expression is widely used to confirm the diagnosis of MCL.
- SOX11 as a Diagnostic Marker
SOX11 is a transcription factor that is highly expressed in MCL. Immunohistochemical detection of SOX11 expression can help differentiate MCL from other lymphomas with similar morphological features.
Genomic analysis of MCL can provide additional insights into the disease biology and guide personalized therapy strategies. MCL was identified by detecting genetic alterations such as TP53 mutation, ATM deletion, and NOTCH1 mutation.
- Ki-67 Staining
The proliferation index, as determined by Ki-67 staining, is another valuable diagnostic tool for MCL. High Ki-67 expression indicates a higher proliferative rate and is associated with a more aggressive clinical course.
Therapy Development of Mantle Cell Lymphoma (MCL)
Monoclonal Antibodies
In the case of MCL, CD20 and CD52 are commonly targeted antigens. Rituximab, an anti-CD20 mAb, has shown efficacy in combination with chemotherapy regimens for MCL. It improves response rates, progression-free survival, and overall survival. Alemtuzumab, an anti-CD52 mAb, has also demonstrated activity in MCL, particularly in relapsed/refractory cases.
Chimeric Antigen Receptor (CAR) T-cell Therapy
CAR T-cell therapy involves genetically modifying T cells to express a receptor that recognizes a specific antigen in cancer cells. In MCL, targeting CD19 with CAR T-cell therapy has shown promise. Clinical trials evaluating CAR T-cell therapy in MCL have reported significant response rates and durable remissions.
Gene Therapy
Gene therapy holds tremendous potential for the therapy of MCL by introducing genetic material into cells to correct or modulate disease-related gene expression. Several gene therapy approaches are being investigated for MCL, including gene editing, gene silencing, and targeted gene delivery.
Our Services
The convergence of cell and genetic technologies brings hope to the research of MCL, and we provide comprehensive MCL diagnostics and therapy development services, including immunotherapy, gene therapy, and other groundbreaking therapy development.
MCL Therapy Development Platforms
Animal models are conducive to in-depth research on MCL. At our company, we advance MCL research with professional skills and advanced platforms, including drug safety evaluation and pharmacokinetic analysis.
Our MCL animal model development services include but are not limited to
- MCL cell lines (Mino, Rec-1, Hbl-2, and Granta-519) derived models
- Patient-derived primary cells xenograft models
- Double transgenic murine models
If you are interested in our services, please feel free to contact us for more details and quotation information of related services.
References
- Wagner, Vivian Petersen, et al. "Mantle cell lymphoma, malt lymphoma, small lymphocytic lymphoma, and follicular lymphoma of the oral cavity: An update." Journal of Oral Pathology & Medicine 50.6 (2021): 622-630.
- Jain, Preetesh, and Michael Wang. "Mantle cell lymphoma: 2019 update on the diagnosis, pathogenesis, prognostication, and management." American journal of hematology 94.6 (2019): 710-725.
All of our services and products are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.